Relapse Rate as a Major Determinant of Drug Selection in Peptic Ulcer Therapy
- 1 April 1988
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 35 (4) , 329-333
- https://doi.org/10.2165/00003495-198835040-00001
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Post-investigation of 687 Medically Treated Cases of Peptic UlcerActa Medica Scandinavica, 2009
- Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?BMJ, 1986
- CAMPYLOBACTER PYLORIDIS, UREASE, HYDROGEN ION BACK DIFFUSION, AND GASTRIC ULCERSThe Lancet, 1986
- THE CHOICE OF ULCER HEALING AGENT INFLUENCES DUODENAL ULCER RELAPSE RATE AND LONG‐TERM CLINICAL OUTCOMEAustralian and New Zealand Journal of Medicine, 1985
- Normal and pathological microbial flora of the upper gastrointestinal tractScandinavian Journal of Gastroenterology, 1985
- MICROBES, PEPTIC ULCER, AND RELAPSE RATES WITH DIFFERENT DRUGSThe Lancet, 1984
- MODEL OF MEDICAL TREATMENT FOR DUODENAL ULCERThe Lancet, 1981
- Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patientsJournal of Neurology, Neurosurgery & Psychiatry, 1977
- Encéphalopathies myocloniques iatrogènes aux sels de bismuthJournal of the Neurological Sciences, 1976
- ROLE OF ANTICHOLINERGIC DRUGS IN TREATMENT OF PEPTIC ULCERJAMA, 1953